JNJ Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of 11.99% compared to Johnson & Johnson's net margin of 10.18%. Johnson & Johnson's return on equity of 20.88% beat Bristol-Myers Squibb's return on equity of -33.18%.

Johnson & Johnson has a consensus price target of $171.66, signalling upside risk potential of 20.66%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $61.05 which suggests that it could grow by 7.47%. Given that Johnson & Johnson has higher upside potential than Bristol-Myers Squibb, analysts believe Johnson & Johnson is more attractive than Bristol-Myers Squibb.

Johnson & Johnson has a beta of 0.514, which suggesting that the stock is 48.607% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.449, suggesting its less volatile than the S&P 500 by 55.097%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.45%. Bristol-Myers Squibb offers a yield of 4.26% to investors and pays a quarterly dividend of $0.62 per share. Johnson & Johnson pays 33.48% of its earnings as a dividend. Bristol-Myers Squibb pays out 59.12% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Bristol-Myers Squibb quarterly revenues of $11.9B. Johnson & Johnson's net income of $2.7B is higher than Bristol-Myers Squibb's net income of $1.2B. Notably, Johnson & Johnson's price-to-earnings ratio is 23.52x while Bristol-Myers Squibb's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 3.94x versus 2.43x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 11.99% compared to Johnson & Johnson's net margin of 8.48%. Johnson & Johnson's return on equity of 20.88% beat Eli Lilly and's return on equity of 66.4%.

Johnson & Johnson has a consensus price target of $171.66, signalling upside risk potential of 20.66%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25%. Given that Eli Lilly and has higher upside potential than Johnson & Johnson, analysts believe Eli Lilly and is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.514, which suggesting that the stock is 48.607% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.45%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. Johnson & Johnson pays 33.48% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Eli Lilly and quarterly revenues of $11.4B. Johnson & Johnson's net income of $2.7B is higher than Eli Lilly and's net income of $970.3M. Notably, Johnson & Johnson's price-to-earnings ratio is 23.52x while Eli Lilly and's PE ratio is 85.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 3.94x versus 17.42x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 11.99% compared to Johnson & Johnson's net margin of 18.95%. Johnson & Johnson's return on equity of 20.88% beat Merck &'s return on equity of 29.26%.

Johnson & Johnson has a consensus price target of $171.66, signalling upside risk potential of 20.66%. On the other hand Merck & has an analysts' consensus of $127.73 which suggests that it could grow by 27.92%. Given that Merck & has higher upside potential than Johnson & Johnson, analysts believe Merck & is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.514, which suggesting that the stock is 48.607% less volatile than S&P 500. In comparison Merck & has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.989%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.45%. Merck & offers a yield of 3.13% to investors and pays a quarterly dividend of $0.81 per share. Johnson & Johnson pays 33.48% of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Merck &'s is not.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Merck & quarterly revenues of $16.7B. Johnson & Johnson's net income of $2.7B is lower than Merck &'s net income of $3.2B. Notably, Johnson & Johnson's price-to-earnings ratio is 23.52x while Merck &'s PE ratio is 20.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 3.94x versus 4.02x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 11.99% compared to Johnson & Johnson's net margin of 25.23%. Johnson & Johnson's return on equity of 20.88% beat Pfizer's return on equity of 4.63%.

Johnson & Johnson has a consensus price target of $171.66, signalling upside risk potential of 20.66%. On the other hand Pfizer has an analysts' consensus of $31.78 which suggests that it could grow by 18.3%. Given that Johnson & Johnson has higher upside potential than Pfizer, analysts believe Johnson & Johnson is more attractive than Pfizer.

Johnson & Johnson has a beta of 0.514, which suggesting that the stock is 48.607% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.45%. Pfizer offers a yield of 6.26% to investors and pays a quarterly dividend of $0.42 per share. Johnson & Johnson pays 33.48% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Pfizer quarterly revenues of $17.7B. Johnson & Johnson's net income of $2.7B is lower than Pfizer's net income of $4.5B. Notably, Johnson & Johnson's price-to-earnings ratio is 23.52x while Pfizer's PE ratio is 36.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 3.94x versus 2.57x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.